Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol DOI Open Access
José Manuel Quesada‐Gómez, José López‐Miranda, Marta Entrenas Castillo

et al.

Nutrients, Journal Year: 2022, Volume and Issue: 14(13), P. 2716 - 2716

Published: June 29, 2022

The COVID-19 pandemic is the greatest challenge facing modern medicine and public health systems. viral evolution of SARS-CoV-2, with emergence new variants in-creased infectious potential, a cause for concern. In addition, vaccination coverage remains in-sufficient worldwide. Therefore, there need to develop therapeutic options, and/or optimize repositioning drugs approved other indications COVID-19. This may include use calcifediol, prohormone vitamin D endocrine system (VDES) as it have potential useful effects treatment We review aspects associating VDES calcifediol in VDES/VDR stimulation enhance innate antiviral effector mechanisms, facilitating induction antimicrobial peptides/autophagy, critical modulatory role subsequent host reactive hyperinflammatory phase during COVID-19: By decreasing cytokine/chemokine storm, regulating renin–angiotensin–bradykinin (RAAS), modulating neutrophil activity maintaining integrity pulmonary epithelial barrier, stimulating repair, directly indirectly increased coagulability prothrombotic tendency associated severe its complications. Available evidence suggests that stimulation, while optimal serum 25OHD status, patients SARS-CoV-2 infection significantly reduce risk acute respiratory distress syndrome (ARDS) COVID-19, possible beneficial on mechanical ventilation intensive care unit (ICU) admission, well deaths course disease. pharmacokinetic functional characteristics give superiority rapidly optimizing levels A pilot study several observational intervention studies using high doses (0.532 mg day 1 0.266 days 3, 7, 14, 21, 28) dramatically decreased ICU admission mortality rate. We, therefore, propose at described rapid correction deficiency all early stages association, if necessary, oral agents.

Language: Английский

Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes DOI Creative Commons
Iacopo Chiodini, Davide Gatti, Davide Soranna

et al.

Frontiers in Public Health, Journal Year: 2021, Volume and Issue: 9

Published: Dec. 22, 2021

Background: Several studies suggest an association between serum 25-hydroxyvitamin D (25OHD) and the outcomes of Severe Acute Respiratory Syndrome Corona-Virus-2 (SARS-CoV-2) infection, in particular Coronavirus Disease-2019 (COVID-19) related severity mortality. The aim present meta-analysis was to investigate whether vitamin status is associated with COVID-19 severity, defined as ARDS requiring admission intensive care unit (ICU) or mortality (primary endpoints) susceptibility SARS-CoV-2 COVID-19-related hospitalization (secondary endpoints). Methods: A search PubMed, ScienceDirect, Web Science, Google Scholar, Scopus, preprints repositories performed until March 31th 2021 identify all original observational reporting measures, enough data calculate them, Vitamin (insufficiency <75, deficiency <50, severe <25 nmol/L) risk hospitalization, ICU admission, death during hospitalization. Findings: Fifty-four (49 fully-printed 5 pre-print publications) were included for a total 1,403,715 individuals. SARS-CoV2 reported 17, 9, 27, 35 studies, respectively. deficiency, insufficiency (odds ratio [OR], 95% confidence intervals [95%CIs]: 2.63, 1.45–4.77; 2.16, 1.43–3.26; 2.83, 1.74–4.61, respectively), (OR, 95%CIs: 2.60, 1.93–3.49; 1.84, 1.26–2.69; 4.15, 1.76–9.77, infection 1.68, 1.32–2.13; 1.83, 1.43–2.33; 1.49, 1.16–1.91, respectively) 95%CIs 2.51, 1.63–3.85; 2.38, 1.56–3.63; 1.82, 1.43–2.33). Considering specific subgroups (i.e., Caucasian patients, high quality adjusted estimates) results primary endpoints did not change. Interpretations: Patients low levels increased due higher

Language: Английский

Citations

152
The Impact of Vitamin D Level on COVID-19 Infection: Systematic Review and Meta-Analysis DOI Creative Commons
Amare Teshome, Aynishet Adane,

Biruk Girma

et al.

Frontiers in Public Health, Journal Year: 2021, Volume and Issue: 9

Published: March 5, 2021

Background: Coronavirus disease (COVID-19) is a respiratory and systemic disorder caused by Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) or novel (nCoV). To date, there no proven curative treatment for this virus; as result, prevention remains to be the best strategy combat coronavirus infection (COVID-19). Vitamin D deficiency (VDD) has been proposed play role in However, conclusive evidence on its impact COVID-19 infection. Therefore, present review aimed summarize available regarding association between levels risk of Methods: A systematic literature search databases (PUBMED/MEDLINE, Cochrane/Wiley library, Scopus, SciELO) were conducted from May 15, 2020, December 20, 2020. Studies that assessed effect vitamin level COVID-19/SARS-2 considered review. The qualities included studies evaluated using JBI tools. Meta-analysis with random-effects model was odds ratio their 95%CI reported. This meta-analysis are reported according preferred reporting items (PRISMA) guideline. Results: electronic supplementary searches yielded 318 records which, only 14 them met inclusion criteria. qualitative synthesis indicated deficient individuals at higher compared sufficient patients. pooled analysis showed Vitamin-D 80% more likely acquire those who have (OR = 1.80; 95%CI: 1.72, 1.88). Begg's test also revealed significant publication bias ( P 0.764). subgroup acquiring relatively case-control study design 1.81). Conclusions: In conclusion, low serum 25 (OH) significantly associated limited currently data suggest decreased

Language: Английский

Citations

125
Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all? DOI Creative Commons
John P. Bilezikian, Anna Maria Formenti, Robert A. Adler

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2021, Volume and Issue: 22(4), P. 1201 - 1218

Published: Dec. 1, 2021

The 4

Language: Английский

Citations

121
Prognostic and Therapeutic Role of Vitamin D in COVID-19: Systematic Review and Meta-analysis DOI Open Access
Harsha Dissanayake, Nipun Lakshitha de Silva, Manilka Sumanatilleke

et al.

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2021, Volume and Issue: 107(5), P. 1484 - 1502

Published: Dec. 11, 2021

Abstract Purpose Vitamin D deficiency/insufficiency may increase the susceptibility to coronavirus disease 2019 (COVID-19). We aimed determine association between vitamin and COVID-19, its severity, mortality, role of in treatment. Methods searched CINAHL, Cochrane library, EMBASE, PubMED, Scopus, Web Science up May 30, 2021, for observational studies on severe disease, death among adults, and, randomized controlled trials (RCTs) comparing treatment against standard care or placebo, improving severity mortality adults with COVID-19. Risk bias was assessed using Newcastle-Ottawa scale AUB-KQ1 tool RCTs. Study-level data were analyzed RevMan 5.3 R (v4.1.0). Heterogeneity determined by I2 sources explored through prespecified sensitivity analyses, subgroup meta-regressions. Results Of 1877 search results, 76 satisfying eligibility criteria included. Seventy-two included meta-analysis (n = 1 976 099). increased odds developing COVID-19 (odds ratio [OR] 1.46; 95% CI, 1.28-1.65; P < 0.0001; 92%), (OR 1.90; 1.52-2.38; 81%), 2.07; 1.28-3.35; 0.003; 73%). The 25-hydroxy concentrations lower individuals compared controls (mean difference [MD] -3.85 ng/mL; -5.44 -2.26; ≤ 0.0001), patients nonsevere (MD -4.84 -7.32 -2.35; 0.0001) nonsurvivors survivors -4.80 -7.89 -1.71; 0.002). insignificant when high risk reporting unadjusted effect estimates excluded. heterogeneity across all analyses. Discrepancies timing testing, definitions partly explained heterogeneity. Four RCTs widely heterogeneous precluding meta-analysis. Conclusion Multiple involving nearly 2 million suggest increases although a Association less robust. precluded their

Language: Английский

Citations

119
Vitamin D supplementation for the treatment of COVID-19: a living systematic review DOI

Julia Kristin Stroehlein,

Julia Wallqvist,

Claire Iannizzi

et al.

Cochrane library, Journal Year: 2021, Volume and Issue: 2021(5)

Published: May 24, 2021

Language: Английский

Citations

109
Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial DOI
Miguel Ángel Villasís-Keever, Mardia López‐Alarcón, Marı́a Guadalupe Miranda-Novales

et al.

Archives of Medical Research, Journal Year: 2022, Volume and Issue: 53(4), P. 423 - 430

Published: April 18, 2022

Language: Английский

Citations

85
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis DOI Creative Commons
Oriana D’Ecclesiis,

Costanza Gavioli,

Chiara Martinoli

et al.

PLoS ONE, Journal Year: 2022, Volume and Issue: 17(7), P. e0268396 - e0268396

Published: July 6, 2022

To assess the evidence on SARS-CoV2 infection and Covid-19 in relation to deficiency supplementation of vitamin D, we conducted a systematic review up April 2021. We summarised data from 38 eligible studies, which presented risk estimates for at least one endpoint, including two RCT 27 cohort-studies: 205565 patients with information 25OHD status 2022 taking D total 1197 admitted ICU or who needed invasive mechanical ventilation intubation hospital stay, more than 910 deaths. Primary outcomes were severity mortality main aim was evaluate association supplementation. Random effects models showed that associated significant lower both severe disease (SRR 0.38, 95% CI 0.20-0.72, 6 studies) 0.35, 0.17-0.70, 8 studies). There no statistically dose differences between studies: summary regular doses remain significant, suggesting higher are not necessary. For supplementation, greater reduction emerged older individuals latitudes. Regarding quality assessed using New Castle-Ottawa scale, analysis revealed most cases low, medium high studies. found associations Covid-19, encompassing risks worsening mortality, especially seasons characterized by patients. Dedicated randomized clinical studies encouraged confirm these results.

Language: Английский

Citations

71
Blood omega-3 fatty acids and death from COVID-19: A pilot study DOI Creative Commons
Arash Asher, Nathan Tintle, Michael Myers

et al.

Prostaglandins Leukotrienes and Essential Fatty Acids, Journal Year: 2021, Volume and Issue: 166, P. 102250 - 102250

Published: Jan. 20, 2021

Very-long chain omega-3 fatty acids (EPA and DHA) have anti-inflammatory properties that may help reduce morbidity mortality from COVID-19 infection. We conducted a pilot study in 100 patients to test the hypothesis RBC EPA+DHA levels (the Omega-3 Index, O3I) would be inversely associated with risk for death by analyzing O3I banked blood samples drawn at hospital admission. Fourteen died, one of 25 quartile 4 (Q4) (O3I ≥5.7%) 13 75 Q1-3. After adjusting age sex, odds ratio an Q4 vs Q1-3 was 0.25, p = 0.07. Although not meeting classical criteria statistical significance, this strong trend suggests relationship indeed exist, but more well-powered studies are clearly needed.

Language: Английский

Citations

99
“Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis” DOI Open Access
Dimple Rawat, Avishek Roy, Souvik Maitra

et al.

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2021, Volume and Issue: 15(4), P. 102189 - 102189

Published: June 28, 2021

Language: Английский

Citations

92
Effects of the COVID pandemic on pregnancy outcomes DOI

Maab Elsaddig,

Asma Khalil

Best Practice & Research Clinical Obstetrics & Gynaecology, Journal Year: 2021, Volume and Issue: 73, P. 125 - 136

Published: March 19, 2021

Pregnant women and neonates are often categorised as being at high risk during the coronavirus disease-2019 (COVID-19) pandemic. Numerous studies have demonstrated that characteristics of COVID-19 disease in pregnant non-pregnant very similar. However, with third trimester more likely than their counterparts to require intensive care, though this may reflect a lower threshold for intervention rather serious disease. Compared without COVID-19, symptomatic requiring admission hospital worse maternal outcomes, including death, although absolute remains low. Outcomes born positive generally good, iatrogenic preterm birth is common. Findings from these highlight need further monitoring outcomes post-partum according

Language: Английский

Citations

86